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Edited by Lukas HuberAbstract Smad3 is an important component of transforming
growth factor-b (TGFb) intracellular signalling. To identify
novel interacting proteins of Smad3, we performed pull-down
assays with Smad3 constructs fused to glutathione-S-transferase.
Proteins which formed complexes with these constructs were
analyzed by two-dimensional gel electrophoresis, and were
identiﬁed by matrix-assisted laser desorption-ionization time-
of-ﬂight mass spectrometry. We identiﬁed 14 proteins interact-
ing with the Smad3 construct lacking the N-terminal Mad
homology domain 1 (MH1), and 12 proteins interacting with the
construct lacking the C-terminal MH2 domain. Proteins
involved in signalling processes, in metabolism regulation, novel
proteins, and components of cytoskeleton form four groups of
interacting proteins. Interactions of AGP7, sex-determining
region Y protein, actin b and sterol regulatory element binding
protein-2 (SREBP-2) proteins with Smad3 constructs were
conﬁrmed by immunoblotting with speciﬁc antibodies. Interac-
tion of Smad3 with SREBP-2 was also conﬁrmed by co-
immunoprecipitation of myc-Smad3 and Flag-SREBP-2 upon
expression in mammalian cells. We found that SREBP-2
inhibited the transcriptional activity of Smad3 in luciferase
reporter assays.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Smad proteins are crucial components of the intracellular
transforming growth factor-b (TGFb)-dependent signalling. In
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doi:10.1016/j.febslet.2004.09.069scribed [1–3]. The ﬁrst group contains receptor-regulated
Smads, with Smad2 and Smad3 being directly phosphorylated
by TGFb and activin receptors, and Smad1, Smad5 and
Smad8 being activated by bone morphogenic protein recep-
tors. The second group has only one member in mammals,
Smad4, which is a common mediator. Smad4 forms complexes
with receptor-regulated Smads and participates in the regula-
tion of gene transcription. The third group contains Smad6
and Smad7 which, despite their structural homology to other
Smads, are negative regulators of TGFb signalling [1–3].
In Smad proteins, three structural regions have been iden-
tiﬁed. The N-terminal and the C-terminal parts, which contain
the Mad homology-1 (MH1), and the MH2 domains, respec-
tively [4]. These two domains are connected by a linker region
which probably does not have a domain structure. The MH1
domain of certain Smads, including Smad3, binds directly to
DNA, while the MH2 domain mediates homo- and hetero-
oligomerization between Smad proteins. The linker region was
claimed to regulate Smad localization in cells and regulates
stability of Smads. All three parts of Smad3 have been shown
to interact with a number of proteins [1–4]. Interacting pro-
teins signiﬁcantly aﬀect functions of Smad proteins, forming
various complexes depending on an activation status of
Smads. For instance, TGFb-induced interaction with the
transcriptional co-activator CBP/p300 strongly promotes
Smad-dependent gene expression [5,6], and an interaction with
the transcriptional co-repressors Ski/Sno suppresses the tran-
scriptional activity of Smad3 [7].
Proteomics technologies have proven to be eﬃcient tools in
studies of protein complexes [8–13]. An analysis of proteins
interacting with 32 known components of the TNFa signalling
pathway unveiled novel modulators of the signalling [13]. In an
application to the TGFb family signalling, we have described a
number of novel interacting proteins of bone morphogenetic
protein receptor-II [12]. Here, we performed a screen for in-
teracting proteins using a pull-down assay with two constructs
of Smad3, the ﬁrst encompassing the N-terminal MH1 domain
and the linker region, and the second containing the C-ter-
minal domain and the linker region, fused to glutathione-
S-transferase (GST). Interacting proteins were resolved by
two-dimensional gel electrophoresis (2D-GE) and were iden-
tiﬁed by peptide mass ﬁngerprinting by matrix-assisted laser
desorption-ionization time-of-ﬂight mass spectrometry
(MALDI TOF MS). We identiﬁed 25 proteins in 26 proteinblished by Elsevier B.V. All rights reserved.
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explored the eﬀect of one of the interacting proteins, sterol
regulatory element binding protein (SREBP-2), on the tran-
scriptional activity of Smad3.Fig. 1. Constructs of Smad3 used in this study. (A) Schematic pre-
sentation of GST-fusion constructs used in this study, compared to the
full-length Smad3 protein. The MH1 and MH2 domains and the linker
region are indicated. (B) Puriﬁed GST-Smad3 constructs and GST
alone were separated by SDS–PAGE. Gel was stained with Coomassie
Brilliant Blue to visualize proteins. Migration positions of proteins are
shown by arrows. Migration positions of molecular mass markers are
shown on the side of the gel.2. Materials and methods
2.1. GST fusion constructs of Smad3
GST fusion constructs used in this study were generated by cloning
the Smad3 MH1 domain and the linker (Met1-Glu321; GST-Smad3-
MH1L), and the linker region and the MH2 domain (Pro135-Ser424;
GST-Smad3-LMH2) into a pGEX-4T-1 vector. The proteins were
expressed in DH5a cells and were puriﬁed according to standard
protocols using glutathione–Sepharose (Amersham Biosciences, Upp-
sala, Sweden).
2.2. Sample preparation
Mv1Lu, 293T, COS7 and HepG2 cell lines were obtained from
ATCC and were maintained in DMEM containing 10% FBS. For GST
pull-down assays Mv1Lu mink lung epithelial cells were used. Label-
ling was performed for 4 h or for 6 h in a methionine/cysteine-free
medium with 20 lCi/ml of labelling mix (ProMix, Amersham Bio-
sciences, Sweden). The proteins were extracted with a lysis buﬀer
containing 1% Triton X-100, 20 mM Tris, pH 7.5, 150 mM NaCl, 10
lg/ml aprotinin and 1 mM PMSF. Equal amounts of GST-fusion-
proteins were added to the cell lysate (lysate from 6 106 cells per pull
down) and incubated overnight at 4 C. After 3 washes with ice-cold
lysis buﬀer, the samples were washed once with 20 mM Tris, pH 7.4,
and resuspended in a sample buﬀer for isoelectric focusing (8 M urea,
4% CHAPS, 0.5% dithiothreitol (DTT), and IPG buﬀer, pH 3–10).
2.3. Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis was performed as described
earlier [12]. Brieﬂy, samples were subjected to isoelectric focusing using
IPGDry strips with immobilized pH gradient, pH range 3–10, 18 cm,
linear (Amersham Biosciences, Sweden). 2D-GE was performed ac-
cording to the protocol described by Hassel et al. [12]. SDS–PAGE was
performed in 10% or in 12% polyacrylamide gels. Two gels per each
running and 35S labelling condition were generated. After the elec-
trophoresis, gels were ﬁxed in 10% acetic acid and 20% methanol for
10–12 h. Proteins were detected by silver staining, as described earlier
[14]. Gels were dried and scanned in a FujiX2000 phosphorimager
(Fuji, Japan). The pH gradient of the ﬁrst-dimension electrophoresis
was evaluated as proposed by the manufacturer of the strips. Totally,
15 gels with samples from three experiments were prepared and sub-
jected to analysis.
2.4. Gel analysis
Silver stained gels were scanned in an ImageScanner with the
MagicScan32 software and analyzed by the ImageMaster 2D Elite
software (Amersham Biosciences, Sweden). Gels were exposed in a
FujiX2000 phosphorimager and scanned using the AIDA software
(IMG GmbH, Germany). Images of silver stained gels and images of
35S labelled proteins in the same gels were compared. As 35S labelled
proteins originate from Mv1Lu cells, this comparison allows distin-
guishing on silver stained gels between co-precipitated Mv1Lu proteins
and non-labelled proteins which originate from bacteria, including
GST fusion protein fragments. Cellular proteins, which speciﬁcally co-
precipitated with Smad3 constructs and not with GST alone, were
selected for identiﬁcation.
2.5. Protein identiﬁcation
Protein spots were excised from the gels, destained and subjected to
in-gel digestion with trypsin (modiﬁed, sequence grade porcine, Pro-
mega, Madison, WI, USA), as described earlier [14,15]. Tryptic pep-
tides were concentrated and desalted on a ‘‘nano-column’’ [16].
Peptides were eluted with about 65% acetonitrile, containing the ma-
trix a-cyano-4-hydroxycinnamic acid, and applied directly onto the
metal target and analyzed by MALDI TOF MS on a Bruker Biﬂex
(Bruker Daltonics, Bremen, Germany). Peptide spectra were internally
calibrated using autolytic peptides from trypsin. To identify proteins,
we performed searches in the NCBInr sequence database using the
ProFound (http://65.219.84.5/service/prowl/profound.html) searchengine. One miscut, alkylation, and partial oxidation of methionine
were allowed. Signiﬁcance of the identiﬁcation was evaluated accord-
ing to the probability value, ‘‘Z’’ value, and sequence coverage.
2.6. Immunoblotting
GST pull-down assay was performed as described in sample prepa-
ration (2.2), using mink Mv1Lu and human HeLa cells. Proteins were
subjected to SDS–PAGE, transferred to nitrocellulose membrane, and
subjected to immunoblotting with antibodies speciﬁc to AGP7 (K-17;
SantaCruz), sex-determining regionYprotein (SRY;C-17; SantaCruz),
actin b (C-11; Santa Cruz), and SREBP-2 (gift from Maria Teresa
Bengoechea Alonso and Johan Ericsson) as described earlier [12].
2.7. Co-precipitation
COS7 cells were transiently transfected with myc-Smad3, Flag-
SREBP-2 and constitutively active TbR-I, as indicated in Fig. 4.
Constitutively active TbR-I was used to initiate TGFb signalling.
Twenty-four hours after transfection, cells were treated with TGFb1
(10 ng/ml), as indicated in Fig. 4. Then, cells were harvested and the
extract was clariﬁed by centrifugation. Immunoprecipitation was per-
formed with anti-Flag antibodies (M2, Sigma, USA) to precipitate
Flag-SREBP-2, immunoprecipitate was resolved by SDS–PAGE and
proteins were transferred onto a nitrocellulose membrane. Co-precip-
itated myc-tagged Smad3 was detected by immunoblotting with anti-
myc antibodies (9E10, Santa Cruz, USA). Expression of myc-Smad3
and Flag-SREBP-2 was evaluated by immunoblotting of whole cell
extracts with anti-myc and anti-Flag antibodies.
2.8. Luciferase reporter assay
Luciferase reporter assay was performed as described earlier [17].
Brieﬂy, HepG2 cells were transiently transfected with plasmids en-
coding for myc-Smad3, Flag-SREBP-2, b-galactosidase (pCH110),
and CAGA(12)-luc or Gal4(TK)-luc reporter plasmids. Twenty-four
hours after transfection, cells were treated for the next 24 h with
TGFb1 (10 ng/ml), as indicated in Fig. 5. Cells were harvested, and
luciferase and b-galactosidase activities were measured. Transfection
eﬃciency was normalized to expression of b-galactosidase. Signiﬁcance
of changes was evaluated by the Student’s t test.
Fig. 2. Two-dimensional gels with proteins co-precipitated with Smad3 constructs. Images of two-dimensional gels stained with silver or after ex-
posure in a phosphorimager are shown. The pH gradient of the separation in the ﬁrst dimension is shown on the top of gels, and direction of SDS–
PAGE is shown on the side of the gels. Migration positions of identiﬁed proteins are shown by lines. Annotation of spots is given in Table 1. Due to
variations in intensities of silver staining and intensities of 35S labelling, some of the spots may be poorly visible on the images of whole gels; lines
indicate migration positions of the spots. Images of 2D gels obtained with GST-Smad3-MH1L (A, B, C), GST-Smad3-LMH2 (D, E, F), and GST
only (G) are shown; the left panels show silver stained gel and the right panels show an image of the same gel after exposure in a phosphorimager,
e.g., 35S labelled proteins. Mv1Lu cells were 35S labelled for 4 h (A, D) or for 6 h (B, C, E, F, G). SDS–PAGE was performed in 10% (A, B, D, E, G)
or in 12% (C, F) polyacrylamide gels. Two gels per each condition were generated, totally 6 gels per one Smad3 construct and 3 gels for GST alone,
and protein spots which appeared on both gels for each running condition were considered for further analysis. Representative gels out of 15
generated gels from three experiments are shown.
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3.1. Selection of proteins speciﬁcally interacting with Smad3
The N-terminal MH1 and C-terminal MH2 domains of
Smad3 have distinct structural and functional characteristics;thus, we generated two deletion constructs of Smad3. The ﬁrst
construct lacks the MH1 domain (GST-Smad3-LMH2) and
the second lacks the MH2 domain (GST-Smad3-MH1L)
(Fig. 1). It has to be noted, that the Smad3 constructs were not
modiﬁed by activated TGFb receptors, as they were puriﬁed
Fig. 2 (continued)
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As a receptor-dependent phosphorylation is essential for ac-
tivation of Smad3, we consider that the constructs used in this
work represent Smad3 in non-activated state. Thus, interacting
proteins would represent pre-activation complexes of Smad3.
We observed a number of proteins that co-precipitated with
the generated GST fusion constructs of Smad3, as well as with
the GST alone (Fig. 2). We used 2D gels of 10% and 12%
polyacrylamide concentration, as they showed to be more ef-
ﬁcient in separation of proteins, as compared to 1D SDS–
PAGE (data not shown). An analysis of silver stained gels andimages of 35S labelled proteins was performed to select spe-
ciﬁcally interacting proteins. Notably, only 35S labelled pro-
teins, co-precipitating with GST-Smad3 constructs, but not
with GST alone, were selected. As a source of interacting
proteins, we used Mv1Lu cells, which have been widely used in
studies of TGFb signalling in epithelial cells and have intact
TGFb/Smad-dependent signalling [18]. A number of proteins
was found to interact with GST constructs non-speciﬁcally, as
they were precipitated with GST alone (Fig. 2; data not
shown). Totally, we selected 45 protein spots for identiﬁcation
of proteins by peptide mass ﬁngerprinting. Twenty-ﬁve pro-
Fig. 2 (continued)
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Smad3 constructs (p06 and p13; Table 1). The remaining 19
proteins were identiﬁed ambiguously and will not be discussed.Table 1
Smad3 interacting proteins Proteins forming complexes with various constru
Number
of spota
Construct
usedb
Name of protein Accession No.c Probabil
P01 MH1L AGP7 (APG7) NP_083111 1.0e+ 00
p02 MH1L KIAA1354 NP_061335 1.0e+ 00
p03 MH1L Ornithine decarboxylase,
chain A
7ODCA 1.0e+ 00
p04 MH1L EPB41 AAH39079 1.0e+ 00
p05 MH1L Oocyte-testis gene 1 NP_739563 1.0e+ 00
p06 MH1L Vimentin
(source: ﬁbroblast)
AAA61281 9.8e) 00
p07 MH1L Smad3 NP_005893 1.0e+ 00
p08 MH1L KIAA1119 BAA86433 9.6e) 00
p09 MH1L Tropomyosin 3 NP_689476 1.0e+ 00
p10 MH1L CT-10 related kinase 3 AAL27153 9.6e) 00
p11 MH1L SREBP-2d AAA85718 7.3e) 00
p12 LMH2 Lamin A CAA53945 9.9e) 00
p13 LMH2 Vimentin A25074 9.9e) 00
p14 LMH2 Splicing factor 3A NP_005868 9.8e) 00
p15 LMH2 Actin, beta AAH08633 1.0e+ 00
p16 LMH2 Sex-determining
region Y (SRY)
AAL68650 1.0e+ 00
p17 LMH2 Glycogen phosphorylase NP_005600 1.0e+ 00
p18 LMH2 Junctophilin 3 NP_065630 1.0e+ 00
p19 LMH2 Keratin 10, type I KRHU0 1.0e+ 00
p20 LMH2 Interleukin 1 NP_055254 1.0e+ 00
p21 LMH2 Pregnancy-associated
endometrial a2-globulin
AAA35802 1.0e+ 00
p22 LMH2 Hypothetical protein XP_297429 9.8e) 00
p23 LMH2 Keratin 2a NP_000414 9.6e) 00
p24 LMH2 Zinc ﬁnger, DHHC
domain containing
4 protein
NP_082655 9.8e) 00
p25 LMH2 a1,3-Fucosyltransferase BAB68651 9.9e) 00
p26 MH1L RBAP2 AAF21796 9.7e) 00
aNumbers of selected protein spots from silver-stained and 35S labelled gels
b LMH2, GST-Smad3-LMH2; MH1L, GST-Smad3-MH1L.
cNCBInr sequence identiﬁcation numbers. Probability, Z-value, coverage an
calculation of experimental pI and Mr was based on migration of proteins on
after resolving of Smad3 interacting proteins in 1D SDS–PAGE.
d SREBP-2 is included in the Table 1, as its interaction with Smad3 was con
malian cells.Fourteen proteins formed a complex with the GST-Smad3-
LMH2 construct and 12 proteins interacted with the GST-
Smad3-MH1L construct.cts of GST-Smad3 were identiﬁed by 2D-GE and MALDI TOF MS
ityc ‘‘Z’’
Value
Sequence
coverage
(%)
Experimental
values
Theoretical
values
pI Mr pI Mr
0 2.43 8 5.0 70.0 6.0 78.6
0 1.94 8 5.3 75.0 5.8 72.0
0 2.41 9 5.7 50.0 5.6 47.8
0 2.43 9 5.0 85.0 5.6 81.8
0 1.48 10 5.7 100.0 5.4 105.7
1 1.01 23 5.0 65.0 4.8 41.7
0 2.07 17 6.0 50.0 6.7 48.9
1 0.56 7 8.0 50.0 6.9 215.9
0 2.43 25 4.0 30.0 4.7 28.2
1 0.63 7 8.0 30.0 5.5 31.5
3 0.05 7 5.0 55 5.5 95.00
1 0.76 11 4.0 100.0 6.2 72.9
1 0.80 27 5.0 65.0 5.1 53.7
1 0.71 8 9.0 70.0 5.2 88.9
0 2.06 28 5.5 45.0 5.6 41.3
0 2.43 34 9.0 25.0 10.0 24.6
0 0.84 18 6.0 100.0 6.6 97.5
0 1.84 7 9.0 100.0 9.4 81.6
0 1.96 12 5.0 40.0 5.2 59.7
0 1.93 13 5.5 25.0 6.1 24.6
0 2.04 15 4.5 20.0 5.1 18.6
1 0.73 19 8.0 50.0 10.7 33.9
1 0.58 12 8.5 50.0 8.3 66.1
1 0.65 11 9.0 45.0 9.6 40.4
1 0.70 27 n.a. 60.0 10.2 44.8
1 0.63 9 n.a. 110.0 6.4 106.9
are presented.
d theoretical pI and Mr were obtained from the ProFound search. The
a 2D gel. n.a., data are not available, as p25 and p26 were identiﬁed
ﬁrmed by co-immunoprecipitation of the proteins expressed in mam-
Fig. 3. Conﬁrmation of sex-determining region Y protein, actin b,
AGP7 and SREBP-2 interactions with Smad3. GST pull down assays
were performed with cell extracts from mink Mv1Lu and human HeLa
cells, as indicated. Cells were not treated with TGFb, to identify
proteins which may form pre-activation complexes with Smad3. In-
teracting proteins were subjected to SDS–PAGE, transferred to
membrane, and immunoblotted with antibodies, as indicated. Speciﬁc
antibodies to SRY (A), actin b (B), AGP7 (C) and SREBP-2 (D) were
used to detect co-precipitated proteins, as indicated in panels. Arrows
show migration positions of proteins with expected molecular masses
of SRY, actin b, AGP7 and SREBP-2 proteins. Migration positions of
molecular mass markers are indicated. In panel C, * indicates a protein
band of predicted molecular mass, which was recognized by anti-
AGP7 antibodies. GST-Smad3-MH1L, GST-Smad3-LMH2, and GST
constructs are indicated. Representative experiments out of 2 per-
formed, are shown.
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of the cytoskeleton, or proteins regulating cytoskeleton (p04,
p06, p09, p12, p13, p15, p18, p19 and p23; Table 1). Vimentin
was identiﬁed as a protein which interacted with both Smad3
constructs (p06 and p13), suggesting that the most probable
vimentin-interacting region is in the linker of Smad3. Identi-
ﬁcation of components of the cytoskeleton is in agreement
with the previously reported interaction of Smad3 with the
cytoskeleton [19].
Seven of the identiﬁed proteins have assigned functions in
various signalling processes; four of the proteins are involved
in regulation of transcription (p07, Smad3; p11, SREBP-2;
p16, SRY and p26, RBAP-2), splicing factor 3 (p14) regulates
activation of snRNA, and CT-10 related kinase 3 (CrkIII, p10)
is an adaptor protein. AGP7 protein (p01) has been described
as a protease. SREBP-2 is included in the list of identiﬁed
proteins (Table 1), as its complex formation with Smad3 was
conﬁrmed by co-immunoprecipitation of the proteins ex-
pressed in mammalian cells (Fig. 4). Smad3 protein forms
homo-oligomers in cells [20], and identiﬁcation of endogenous
Smad3 as an interacting protein suggests that conditions of the
assay allowed preservation of physiologically relevant inter-
actions.
Enzymes regulating metabolism of carbohydrates (p17,
glycogen phosphorylase; p25, a1,3-fucosyltransferase) and
ornithine (p03, ornithine decarboxylase) were identiﬁed. The
importance of the Smad3 interaction with metabolic enzymes
remains to be elucidated. Five of the interacting proteins do
not have assigned functions (p02, KIAA1354; p05, oocyte-
testis gene 1; p08, KIAA1119; p22, novel protein; and p24, zinc
ﬁnger, DHHC-domain containing 4 protein).
Twenty-four of the identiﬁed proteins have not been de-
scribed as Smad3 binding molecules; the 25th protein, Smad3
(p07), is suggested to have an intra-molecular interaction be-
tween the MH1 and the MH2 domains. However, 5 of these 24
proteins (25 protein spots, not including Smad3, p07; Table 1)
do not have assigned functions in cells and 13 proteins are
involved in activities which have been described to involve
Smad proteins. The interacting proteins with activities previ-
ously not associated with Smad3 are metabolic enzymes (p03,
p17 and p25), splicing factor 3A (p14) and CT-10 related ki-
nase 3 (CrkIII, p10). Detection of the latter two proteins
suggests that Smad3 may aﬀect activation of snRNA and may
interact with the adaptor protein involved in recognition of a
phosphotyrosine.
3.2. Conﬁrmation of interaction of SRY, actin b, AGP7 and
SREBP-2 proteins with Smad3 by immunoblotting
To conﬁrm observed interactions by an alternative tech-
nique, we performed immunodetection of co-precipitated
proteins in GST pull-down assays. We selected for a conﬁr-
mation study AGP7, SRY, and actin b proteins, as speciﬁc
antibodies were available for these proteins. We also used
human HeLa and mink Mv1Lu cells to explore whether both
mink and human proteins would form a complex with Smad3.
We detected AGP7, SRY, actin b and SREBP-2 proteins co-
precipitated with Smad3 constructs (Fig. 3). SRY and actin b
interacted with a GST-Smad3LMH2 construct, and AGP7
and SREBP-2 interacted with a GST-Smad3MH1L construct.
This is in agreement with the speciﬁcity of interactions ob-
served using 2D-GE and mass spectrometry (Table 1). Weak
interactions of AGP7 with GST-Smad3LMH2 and SRY withGST-Smad3MH1L suggest that the linker region of Smad3
may contribute to the interactions; use of speciﬁc antibodies
increases sensitivity of detection and allows detection of even
weak interactions. Detection of human SRY, actin b, AGP-7
and SREBP-2 proteins in a complex with Smad3 constructs
(Fig. 3) conﬁrmed the ﬁndings made with mink proteins (Figs.
2 and 3, Table 1). This also supports the signiﬁcance of peptide
mass ﬁngerprinting of mink proteins (Table 1) using NCBI
database pool of mammalian proteins.3.3. SREBP-2 forms a complex with Smad3 and inhibits its
transcriptional activity
To further conﬁrm SREBP-2 and Smad3 interaction in vivo,
we transfected Flag-SREBP-2 and myc-Smad3 in COS7 cells,
and performed a co-immunoprecipitation assay. We found
that myc-Smad3 and Flag-SREBP-2 formed a complex in non-
treated cells, while TGFb1 treatment decreased complex for-
mation (Fig. 4). Ligand-independent complex formation be-
tween Flag-SREBP-2 and myc-Smad3 in COS7 cells is in
agreement with the detection of SREBP-2 in the GST pull-
down assay (Figs. 2 and 3D; Table 1), as the bait GST-Smad3
construct resembles a non-activated Smad3.
Smad3 regulates transcription of genes by binding to a
promoter DNA and by interacting with other proteins [1–4].
To explore whether the interaction with SREBP-2 aﬀects the
transcriptional activity of Smad3, we performed assays with
luciferase reporters, sensitive to Smad3 (Fig. 5). CAGA(12)-luc
Fig. 4. Flag-SREBP-2 and myc-Smad3 form a complex in cells. Flag-
SREBP-2, myc-Smad3 and constitutively active mutant of TbR-I were
transfected in COS7 cells. Expression of constitutively active TbR-I
and treatment with TGFb1 (10 ng/ml) were performed to induce
TGFb-dependent signalling, as indicated. myc-Smad3, co-precipitated
with Flag-SREBP-2, was detected with anti-myc antibodies (upper
panel). Expression of myc-Smad3 was monitored by immunoblotting
of a whole cell extract (lower panel). Migration positions of myc-
Smad3 are shown by arrows. Arrowhead shows a non-speciﬁc band
which was detected in all samples. A representative experiment out of 2
performed is shown. WCE, whole cell extract; IP, immunoprecipita-
tion; IB, immunoblotting.
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Fig. 5. SREBP-2 inhibits transcriptional activity of Smad3. Assays
with CAGA(12)-luc (A) and Gal4(TK)-luc (B) luciferase reporters
were performed in HepG2 cells. Cells were transfected with myc-
Smad3 and Flag-SREBP-2 constructs, and treated with TGFb1 (10 ng/
ml), as indicated. Luciferase activity was normalized to the expression
of b-galactosidase. Schematic presentation of activation of CAGA(12)-
luc reporter upon transfection of cells with myc-Smad3 and Flag-
SREBP-2, and treatment with TGFb1 are shown in panel A. *,
P < 0:01, cells transfected with myc-Smad3 compared to cells trans-
fected with myc-Smad3 and Flag-SREBP-2, and treated with TGFb1.
S. Grimsby et al. / FEBS Letters 577 (2004) 93–100 99reporter contains CAGA elements in the promoter, which bind
activated Smad3 directly [21]. Treatment of HepG2 cells with
TGFb1 activated the reporter via endogenous Smad3, as
expected. Expression of myc-Smad3 increased activation and
co-transfection of SREBP-2 with myc-Smad3 inhibited Smad3-
dependent activation of CAGA(12)-luc reporter (Fig. 5A).
Similar results were obtained with Mv1Lu cells (data not
shown).
We also studied the eﬀect of SREBP-2 on the transcriptional
activity of Smad3 in another reporter assay; the Gal4(TK)-luc
reporter is activated speciﬁcally when Smad3 fused to the Gal4
DNA-binding domain is transfected in cells which are treated
with TGFb1 (Fig. 5B) [22]. We found that in this assay
SREBP-2 also inhibited Smad3-dependent transcriptional ac-
tivity induced by the ligand. Thus, in two independent assays
we observed inhibitory eﬀect of SREBP-2 on transcriptional
activity of Smad3. Stronger interaction of SREBP-2 with
Smad3 in the absence of ligand treatment, as compared to
TGFb1-treated cells (Fig. 4), suggests that SREBP-2 may se-
quester Smad3 to inhibit its transcriptional activity (Fig. 5).4. Discussion
Description of protein interaction networks is of importance
for the understanding of protein functions. Here, we identiﬁed
25 proteins that co-precipitated with Smad3 constructs fused
to GST. As GST-Smad3 constructs were not subjected to thereceptor-speciﬁc phosphorylation, they could be considered as
representing a non-activated Smad3. Smad3 in inactive state
was earlier found to interact with microtubules and treatment
with TGFb leads to dissociation of Smad3 from microtubules
[19]. Our ﬁnding that 8 Smad3-interacting proteins are com-
ponents of the cytoskeleton (Table 1) supports the notion that
Smad3 may be bound to the cytoskeleton prior to activation.
Five of these proteins were found to bind to the GST-Smad3-
LMH2 construct and 3 were bound to the GST-Smad3-
MH1L. Conﬁrmation of interactions of Smad3 with SRY,
actin b, AGP7 and SREBP-2 proteins obtained from mink and
human cells by immunoblotting (Fig. 3) suggests that our
proteomics/mass spectrometry-based ﬁndings with mink pro-
teins are also relevant for human proteins. Interaction of actin
b with GST-Smad3LMH2 construct, and no interaction with
GST-Smad3MH1L and GST alone (Fig. 3), suggests that the
identiﬁed components of the cytoskeleton form a complex with
Smad3 speciﬁcally.
Smad3 is a transcription factor and, therefore, interactions
with signalling proteins would be expected. We identiﬁed 7
proteins which have regulatory roles in gene transcription,
splicing of snRNA, and protein degradation. Twenty-four
100 S. Grimsby et al. / FEBS Letters 577 (2004) 93–100proteins identiﬁed in 25 protein spots have not been previously
described as Smad3-binding molecules, increasing the number
of Smad3-interacting proteins to more than 50 [23]. We do not
exclude that some of the interactions with Smad3 may not be
direct, but rather reﬂected formation of multiprotein com-
plexes. Further studies of Smad3 complexes puriﬁed directly
from cells are required to map changes in protein interaction
upon activation of Smad3.
Smad3 interacts with a number of transcriptional regulators,
which modulate Smad3-dependent gene expression [1–4,23].
SREBP-2 is a transcription factor, which stimulates expression
of a number of enzymes of sterol synthesis [24,25]. An inter-
action of Smad3 with SREBP-2, observed by us, may be in-
volved in the inhibitory eﬀect of SREBP-2 on the
transcriptional activity of Smad3 (Figs. 2, 4 and 5). As TGFb
is a potent inhibitor of steroidogenesis [26], it is tempting to
suggest that SREBP-2 may inhibit the anti-steroidogenic ac-
tion of TGFb/Smad3 by sequestering Smad3, thus enhancing
SREBP-2-speciﬁc stimulation of the steroidogenesis. To sup-
port this suggestion, further exploration of Smad3 interaction
with SREBP-2 is required.
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